Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sugarman

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2009
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancerK N Syrigos, J Vansteenkiste, P Parikh, et al.
Chemotherapy Research and Practice|April 7, 2012
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?Karen M Clements, Gerson Peltz, Douglas E Faries, et al.
Lancet (London, England)|September 22, 2009
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyTudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2009
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancerK N Syrigos, J Vansteenkiste, P Parikh, et al.
Chemotherapy Research and Practice|April 7, 2012
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?Karen M Clements, Gerson Peltz, Douglas E Faries, et al.
Lancet (London, England)|September 22, 2009
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyTudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung CancerGiorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Pageof 2